carbamazepine has been researched along with Obesity in 18 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "An autopsy case of carbamazepine overdose with focal myocarditis is reported." | 7.73 | A case of carbamazepine overdose with focal myocarditis. ( Aoki, Y; Niitsu, H; Saigusa, K; Takamiya, M, 2006) |
| "In order to investigate the possible role of valproic acid therapy in the development of obesity, hyperinsulinism and polycystic ovaries (PCOs), we have studied metabolic parameters and ovarian morphology in epileptic women." | 7.71 | Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. ( Abraham, I; Alge, A; Bauer, G; Haslinger, M; Lechleitner, M; Luef, G; Seppi, K; Trinka, E; Unterberger, I; Windisch, J, 2002) |
| "The interaction between clearance of phenytoin, valproic acid, phenobarbital and carbamazepine, and changes in body weight was determined in a 19-year-old obese woman with epilepsy (body weight 93 kg, BMI 36." | 7.69 | Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study. ( Ashikari, Y; Chiba, S; Kodama, Y; Kuranari, M; Sakata, T; Takeyama, M, 1996) |
| "Single-dose (200 mg) carbamazepine pharmacokinetics was evaluated in six obese, otherwise healthy subjects, before and after a mean +/- SEM weight reduction of 30." | 7.68 | Significant weight reduction in obese subjects enhances carbamazepine elimination. ( Berry, EM; Caraco, Y; Levy, M; Zylber-Katz, E, 1992) |
| "Body mass index (BMI) and fasting serum concentrations of insulin and lipids were measured in 102 men with epilepsy who were treated with VPA, carbamazepine (CBZ), or oxcarbazepine (OXC) monotherapy." | 5.10 | Fasting serum insulin and lipid levels in men with epilepsy. ( Isojärvi, JI; Knip, M; Kotila, M; Myllylä, VV; Pakarinen, AJ; Pylvänen, V; Rättyä, J; Turkka, J, 2003) |
| "Our study was carried out to ascertain the role of valproic acid for inducing metabolic disorders like hyperinsulinemia, insulin resistance and metabolic syndrome." | 3.77 | Fasting insulin and HOMA-index changes in patients treated with valproic acid. ( Javashvili, L; Kasradze, S; Mania, M; Okujava, N, 2011) |
| "An autopsy case of carbamazepine overdose with focal myocarditis is reported." | 3.73 | A case of carbamazepine overdose with focal myocarditis. ( Aoki, Y; Niitsu, H; Saigusa, K; Takamiya, M, 2006) |
| " Anthropometric measurements, staging of pubertal maturation, and clinical manifestations of hyperandrogenism were assessed, as well as measurement of serum levels of testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), and free androgen index (FAI)." | 3.72 | Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. ( Abd El-Basset, FZ; El Barbary, NS; El-Khayat, HA; Hakky, SM; Mohamed, MS; Nassef, NM; Tohamy, SM; Tomoum, HY; Zaky, AA, 2004) |
| "In order to investigate the possible role of valproic acid therapy in the development of obesity, hyperinsulinism and polycystic ovaries (PCOs), we have studied metabolic parameters and ovarian morphology in epileptic women." | 3.71 | Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. ( Abraham, I; Alge, A; Bauer, G; Haslinger, M; Lechleitner, M; Luef, G; Seppi, K; Trinka, E; Unterberger, I; Windisch, J, 2002) |
| "The interaction between clearance of phenytoin, valproic acid, phenobarbital and carbamazepine, and changes in body weight was determined in a 19-year-old obese woman with epilepsy (body weight 93 kg, BMI 36." | 3.69 | Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study. ( Ashikari, Y; Chiba, S; Kodama, Y; Kuranari, M; Sakata, T; Takeyama, M, 1996) |
| "Single-dose (200 mg) carbamazepine pharmacokinetics was evaluated in six obese, otherwise healthy subjects, before and after a mean +/- SEM weight reduction of 30." | 3.68 | Significant weight reduction in obese subjects enhances carbamazepine elimination. ( Berry, EM; Caraco, Y; Levy, M; Zylber-Katz, E, 1992) |
| "To study the pharmacokinetics of a combination oral contraceptive (OC) containing norethindrone and ethinyl estradiol during OC monotherapy, concomitant OC and topiramate (TPM) therapy, and concomitant OC and carbamazepine (CBZ) therapy in order to comparatively evaluate the pharmacokinetic interaction, which may cause contraceptive failure." | 2.71 | Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. ( Bialer, M; Doose, DR; Jacobs, D; Padmanabhan, M; Schwabe, S; Wang, SS, 2003) |
| "To compare carbamazepine pharmacokinetic parameters between obese and lean subjects following the administration of a single 200-mg tablet." | 2.68 | Carbamazepine pharmacokinetics in obese and lean subjects. ( Berry, EM; Caraco, Y; Levy, M; Zylber-Katz, E, 1995) |
| " To this end, we developed and verified a physiologically-based pharmacokinetic (PBPK) model for LNG in PK-Sim (version 8." | 1.62 | Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. ( Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H, 2021) |
| "Metabolic syndrome was more frequently associated with VPA-treated patients (41." | 1.34 | Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. ( Kim, JY; Lee, HW, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Cicali, B | 1 |
| Lingineni, K | 1 |
| Cristofoletti, R | 1 |
| Wendl, T | 1 |
| Hoechel, J | 1 |
| Wiesinger, H | 1 |
| Chaturvedula, A | 1 |
| Vozmediano, V | 1 |
| Schmidt, S | 1 |
| Chattopadhyay, I | 1 |
| Adhiyaman, V | 1 |
| Ghiya, S | 1 |
| Terzaghi, M | 1 |
| Sartori, I | 1 |
| Cremascoli, R | 1 |
| Rustioni, V | 1 |
| Manni, R | 1 |
| Janszky, J | 1 |
| Horvath, R | 1 |
| Komoly, S | 1 |
| Mania, M | 1 |
| Javashvili, L | 1 |
| Kasradze, S | 1 |
| Okujava, N | 1 |
| Luef, G | 1 |
| Abraham, I | 1 |
| Haslinger, M | 1 |
| Trinka, E | 1 |
| Seppi, K | 1 |
| Unterberger, I | 1 |
| Alge, A | 1 |
| Windisch, J | 1 |
| Lechleitner, M | 1 |
| Bauer, G | 1 |
| Pylvänen, V | 1 |
| Knip, M | 3 |
| Pakarinen, AJ | 3 |
| Turkka, J | 1 |
| Kotila, M | 1 |
| Rättyä, J | 2 |
| Myllylä, VV | 2 |
| Isojärvi, JI | 3 |
| Doose, DR | 1 |
| Wang, SS | 1 |
| Padmanabhan, M | 1 |
| Schwabe, S | 1 |
| Jacobs, D | 1 |
| Bialer, M | 1 |
| El-Khayat, HA | 1 |
| Abd El-Basset, FZ | 1 |
| Tomoum, HY | 1 |
| Tohamy, SM | 1 |
| Zaky, AA | 1 |
| Mohamed, MS | 1 |
| Hakky, SM | 1 |
| El Barbary, NS | 1 |
| Nassef, NM | 1 |
| George, R | 1 |
| Poonnoose, P | 1 |
| Isaiah, R | 1 |
| Takamiya, M | 1 |
| Aoki, Y | 1 |
| Niitsu, H | 1 |
| Saigusa, K | 1 |
| Kim, JY | 1 |
| Lee, HW | 1 |
| Caraco, Y | 2 |
| Zylber-Katz, E | 2 |
| Berry, EM | 2 |
| Levy, M | 2 |
| Laatikainen, TJ | 1 |
| Juntunen, KT | 1 |
| Kuranari, M | 1 |
| Chiba, S | 1 |
| Ashikari, Y | 1 |
| Kodama, Y | 1 |
| Sakata, T | 1 |
| Takeyama, M | 1 |
| Taubøll, E | 1 |
| van Parys, J | 1 |
| Harbo, HF | 1 |
| Dale, PO | 1 |
| Fauser, BC | 1 |
| Gjerstad, L | 1 |
| Koivunen, R | 1 |
| Tapanainen, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Medications After Adolescent Bariatric Surgery Protocol for Inadequate Weight Loss Following Sleeve Gastrectomy in Adolescents and Young Adults: A Pilot Feasibility Study[NCT04572217] | Phase 2 | 0 participants (Actual) | Interventional | 2022-06-30 | Withdrawn (stopped due to No available funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carbamazepine and Obesity
| Article | Year |
|---|---|
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administratio | 2015 |
3 trials available for carbamazepine and Obesity
| Article | Year |
|---|---|
Fasting serum insulin and lipid levels in men with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Body Mass Index; Carbamazepine; Epilepsy; Fasting; Humans; Hyper | 2003 |
Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Body Mass Index; Carbamazepine; Cont | 2003 |
Carbamazepine pharmacokinetics in obese and lean subjects.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Carbamazepine; Female; Half-Life; Humans; Male; Mid | 1995 |
14 other studies available for carbamazepine and Obesity
| Article | Year |
|---|---|
Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Topics: Adult; Alkynes; Benzoxazines; Body Mass Index; Carbamazepine; Clarithromycin; Computer Simulation; C | 2021 |
Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs).
Topics: Anticoagulants; Carbamazepine; Humans; Obesity; Pulmonary Embolism; Rivaroxaban | 2018 |
Choking in the night due to NFLE seizures in a patient with comorbid OSA.
Topics: Adult; Airway Obstruction; Anticonvulsants; Carbamazepine; Continuous Positive Airway Pressure; Diag | 2014 |
Fasting insulin and HOMA-index changes in patients treated with valproic acid.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Carbamazepine; Cholesterol, HDL; Epilepsy; Female; | 2011 |
Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Insulin Resistance; Obesity; Polycy | 2002 |
Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Dehydroepiandrosterone; Epilepsy; Female; Growth; | 2004 |
Dercum's disease (Adiposis dolorosa): delayed diagnosis in a patient with cervical cancer.
Topics: Adiposis Dolorosa; Adult; Amitriptyline; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antide | 2004 |
A case of carbamazepine overdose with focal myocarditis.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Overdose; Female; Humans; Lymphocytes | 2006 |
Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Carbamazepine; Comorbidity; Epil | 2007 |
Obesity and endocrine disorders in women taking valproate for epilepsy.
Topics: Adult; Body Weight; Carbamazepine; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Endocrine | 1996 |
Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Half-Life; Humans; Metabolic Clearance Rate | 1996 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Altered ovarian function and cardiovascular risk factors in valproate-treated women.
Topics: Adult; Analysis of Variance; Anticonvulsants; Carbamazepine; Cardiovascular Diseases; Case-Control S | 2001 |
Significant weight reduction in obese subjects enhances carbamazepine elimination.
Topics: Administration, Oral; Adult; Body Mass Index; Carbamazepine; Diet, Reducing; Female; Half-Life; Huma | 1992 |